Abu Dhabi’s M42 partners with UK firm to develop AI-driven therapeutics for age-related diseases
Abu Dhabi’s M42 has announced a partnership and investment in UK-based longevity biotech leader Juvenescence. The new alliance is aimed at discovering and developing AI-enabled therapeutics to advance the treatment of life-threatening and age-related diseases and improve healthy lifespan.
M42 and Juvenescence will harness the power of artificial intelligence, genomics, and biobanking to accelerate clinical trials and bring transformative medicines to market faster.
The collaboration was revealed during Abu Dhabi Global Health Week (ADGHW), where M42 is a Foundational Partner.
Hasan Jasem Al Nowais, Managing Director and Group Chief Executive Officer at M42, said, “With this investment and partnership, M42 is taking great strides in reinforcing Abu Dhabi’s push as a global nexus for AI-enabled therapeutics and biomedical innovation to tackle local and international health challenges.”
Age-related conditions such as cardiovascular disease, neurodegeneration, and metabolic disorders are becoming increasingly prevalent due to growing global life expectancy. With the UAE actively pursuing advanced solutions to address the healthcare needs of its aging population, this partnership comes at a critical time.
Al Nowais added, “With Juvenescence, we are unlocking the potential of AI to transform the way we discover and deliver drugs, bringing innovative, life-changing therapies to patients worldwide. This is not just about innovation, it’s about impact – on lives, on science and on the future of health.”
From Abu Dhabi to the world
Further, the partnership will aim to identify novel drug targets and therapeutics, as well as explore collaboration in R&D with leading academic and research organisations globally and support the development of the country’s biotechnology strategy.
Dr Fahed Al Marzooqi, Chief Executive Officer of M42’s Integrated Health Solutions platform and Acting Chief Executive Officer of M42’s AI Life Sciences platform, added, “By uniting AI innovation with biotech expertise, we’re not only advancing the fight against age-related diseases but also building a global ecosystem that empowers prevention, precision, and progress — delivering transformative therapies from Abu Dhabi to the world.”
Dr Richard Marshall, Chief Executive Officer at Juvenescence, said, “Our work together will enable the creation of a unique pipeline of innovative therapeutics that will have enormous potential to target the underlying causes of age-related disease and improve the health span of patients globally.”
